Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial

This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN: Patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days. SETTING: A retrospective analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Karvellas, Constantine J., Subramanian, Ram, Olson, Jody C., Jamil, Khurram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060094/
https://www.ncbi.nlm.nih.gov/pubmed/37007903
http://dx.doi.org/10.1097/CCE.0000000000000890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060094/
https://www.ncbi.nlm.nih.gov/pubmed/37007903
http://dx.doi.org/10.1097/CCE.0000000000000890

Ejemplares similares